Aziz Ullah

Gedatolisib after CDK4/6 inhibition in HR-Positive/HER2-negative advanced breast cancer: pharmacology, phase iii evidence, and therapeutic positioning

INTRODUCTION: Progression following CDK4/6 inhibition remains a therapeutic challenge in hormone receptor-positive, HER2-negative advanced breast cancer. Gedatolisib, an FDA-approved pan-class I PI3K/mTORC1/2 inhibitor, introduces a treatment strategy for disease without a detect...